doi: 10.1038/s41467-021-24859-2 17 AlborziniaHFlrezAFKrethSBrcknerLMYildizUGartlgruberMet al
Signs of compromised water include cloudiness, visible particles, unusual odor, or discoloration
Ozempic for diabetes and Wegovy for weight loss are now familiar brand names for the pharmaceutical compound semaglutide
In total, 114 core publications were selected, encompassing various interventions, including short-term intensive insulin therapy, non-insulin antihyperglycemic agents (e.g., SGLT-2 inhibitors and GLP-1 receptor agonists), and adjunctive therapies (e.g., vitamin D, sex hormones, and Chinese herbal compounds)
Indications and Usage Wegovy (semaglutide) injection is indicated in combination with a reduced calorie diet and increased physical activity: To reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight To reduce excess body weight and maintain weight reduction long term in: Adults and pediatric patients 12 years and older with obesity Adults with overweight in the presence of at least one weight-related comorbidity Wegovy (semaglutide) tablets are indicated in combination with a reduced calorie diet and increased physical activity to: Reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight Reduce excess body weight and maintain weight reduction long term in adults with obesity or with overweight in the presence of at least one weight-related comorbidity Limitations of Use: Concomitant use of Wegovy tablets or Wegovy injection with other semaglutide-containing products or with any GLP-1 receptor agonist is not recommended References Simmonds M, Llewellyn A, Owen CG, Woolacott N
